Niacinamide
|
Basic information |
| Metabolite name | Niacinamide |
 | HMDB0001406 |
 |
C00153 |
 |
936 |
| Synonyms | Nicotinamide; |
| No. of studies | 35 |
|
Basic information |
| Metabolite name | Niacinamide |
| HMDB0001406 |
|
C00153 |
|
936 |
| Synonyms | Nicotinamide; |
| No. of studies | 35 |
|
Relationship between Niacinamide and depression (count: 35) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M050 | Type3 | 14h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M1039 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M105 | Type1 | sCSDS group vs. control group | Liver | C57BL/6JJmsSlc mouse | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Down |
| Study M116 | Type3 | LY group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M116 | Type3 | ketamine group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M147 | Type2 | FSL acute vortioxetine group vs. FSL acute control group | Plasma | Sprague-Dawley rat | Down |
| Study M148 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M150 | Type1 | IFN-alpha group vs. control group | Frontal cortex | Sprague-Dawley rat | Down |
| Study M150 | Type1 | IFN-alpha group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M151 | Type1 | Male FSL group vs. Male FRL group | Plasma | Sprague-Dawley rat | Down |
| Study M204 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Down |
| Study M480 | Type2 | CGA-treated group vs. sleep deprivation group | Urine | Wistar rat | Down |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Up |
| Study M571 | Type1 | LPS group vs. control group | Hypothalamus | CD-1 mouse | Down |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M701 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M826 | Type1 | CVS group vs. control group | Colorectum | Wistar rat | Up |
| Study M826 | Type1 | CVS group vs. control group | Gut | Wistar rat | Up |
| Study M826 | Type2 | CVS + antibiotic group vs. CVS group | Gut | Wistar rat | Down |
| Study M828 | Type1 | ultrasonic radiation group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Faece | BALB/c mouse | Up |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M878 | Type1 | unipolar depression group vs. control group | Plasma | Human | Down |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
| Study M906 | Type2 | after rTMS treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Up |